These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 36409389)
1. Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma. Yousefi Z; Sharifzadeh S; Zare F; Eskandari N Mol Biol Rep; 2023 Feb; 50(2):1133-1145. PubMed ID: 36409389 [TBL] [Abstract][Full Text] [Related]
2. Fc Receptor-Like 1 as a Promising Target for Immunotherapeutic Interventions of B-Cell-Related Disorders. Yousefi Z; Sharifzadeh S; Yar-Ahmadi V; Andalib A; Eskandari N Biomark Insights; 2019; 14():1177271919882351. PubMed ID: 31798301 [TBL] [Abstract][Full Text] [Related]
3. Ning F; Wang H; Liang Z; Lan J Discov Med; 2024 Aug; 36(187):1627-1640. PubMed ID: 39190378 [TBL] [Abstract][Full Text] [Related]
4. Elevated RNA expression of long non‑coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma. Yan Y; Han J; Li Z; Yang H; Sui Y; Wang M Mol Med Rep; 2016 Jun; 13(6):5125-31. PubMed ID: 27122348 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227 [TBL] [Abstract][Full Text] [Related]
6. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling. Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549 [TBL] [Abstract][Full Text] [Related]
7. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503 [TBL] [Abstract][Full Text] [Related]
8. CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma. Shen M; Zhang Y; Tang L; Fu Q; Zhang J; Xu Y; Zeng H; Li Y BMC Cancer; 2023 Oct; 23(1):978. PubMed ID: 37833632 [TBL] [Abstract][Full Text] [Related]
9. Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma. Cui W; Cai Y; Wang W; Liu Z; Wei P; Bi R; Chen W; Sun M; Zhou X J Transl Med; 2014 Jan; 12():10. PubMed ID: 24418330 [TBL] [Abstract][Full Text] [Related]
11. β-TrCP1 promotes cell proliferation via TNF-dependent NF-κB activation in diffuse large B cell lymphoma. Cai N; Chen Z; Huang Y; Shao S; Yu H; Wang Y; He S Cancer Biol Ther; 2020; 21(3):241-247. PubMed ID: 31731887 [TBL] [Abstract][Full Text] [Related]
12. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells. Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343 [TBL] [Abstract][Full Text] [Related]
13. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127 [TBL] [Abstract][Full Text] [Related]
14. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313 [TBL] [Abstract][Full Text] [Related]
15. Fat mass and obesity-associated protein (FTO)-induced upregulation of flotillin-2 (FLOT2) contributes to cancer aggressiveness in diffuse large B-cell lymphoma (DLBCL) via activating the PI3K/Akt/mTOR signal pathway. Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A Arch Biochem Biophys; 2024 Aug; 758():110072. PubMed ID: 38914215 [TBL] [Abstract][Full Text] [Related]
16. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc. Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819 [TBL] [Abstract][Full Text] [Related]
17. Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma. Ramirez E; Singh RR; Kunkalla K; Liu Y; Qu C; Cain C; Multani AS; Lennon PA; Jackacky J; Ho M; Dawud S; Gu J; Yang S; Hu PC; Vega F Leuk Res; 2012 Oct; 36(10):1267-73. PubMed ID: 22809693 [TBL] [Abstract][Full Text] [Related]
18. Chidamide and orelabrutinib synergistically induce cell cycle arrest and apoptosis in diffuse large B-cell lymphoma by regulating the PI3K/AKT/mTOR pathway. Wu C; Chen S; Wu Z; Xue J; Zhang W; Wang S; Xindong Zhao ; Wu S J Cancer Res Clin Oncol; 2024 Feb; 150(2):98. PubMed ID: 38381215 [TBL] [Abstract][Full Text] [Related]
19. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Takagi Y; Shimada K; Shimada S; Sakamoto A; Naoe T; Nakamura S; Hayakawa F; Tomita A; Kiyoi H Cancer Sci; 2016 Sep; 107(9):1270-80. PubMed ID: 27348272 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Fc receptor-like 1 in patients with chronic lymphocytic leukemia, hairy cell leukemia, and various B-cell non-Hodgkin's lymphoma. Yousefi Z; Eskandari N Leuk Res Rep; 2019; 12():100181. PubMed ID: 31467839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]